1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 5,050 | 5,100 | 04.07. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | BIOCYTOGEN-B: HBM HOLDINGS-B 's Invention Patent Lawsuit Claims Dismissed in First Instance | 3 | AASTOCKS | ||
| BIOCYTOGEN PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| Mo | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Gericht gibt Biocytogen im wegweisenden Patentstreit gegen Harbour in Bezug auf RenNano Recht | 362 | Business Wire | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", SSE: 688796; HKEX: 02315) hat heute bekannt gegeben, dass das Gericht für geistiges Eigentum in Shanghai ein erstinstanzliches Zivilurteil... ► Artikel lesen | |
| Mo | BIOCYTOGEN-B (02315): VOLUNTARY ANNOUNCEMENT DEVELOPMENT OF LITIGATION | 2 | HKEx | ||
| 25.06. | BIOCYTOGEN-B (02315): POLL RESULTS OF THE 2026 SECOND EXTRAORDINARY GENERAL MEETING HELD ON JUNE 25, 2026 | 1 | HKEx | ||
| 16.06. | Biocytogen erhält die vollumfängliche AAALAC-Akkreditierung, was die Exzellenz in der translationalen Forschung und der Wirkstoffentdeckung unterstreicht | 289 | Business Wire | Biocytogen teilte heute mit, dass seine Forschungseinrichtung in Boston die Vollakkreditierung durch AAALAC International erhalten hat, eine weltweit renommierte Organisation, deren Ziel die Förderung... ► Artikel lesen | |
| 15.06. | Biocytogen Earns Full AAALAC Accreditation, Reinforcing Excellence in Translational Research and Drug Discovery | 234 | Business Wire | Biocytogen today announced that its Boston research facility has been awarded Full Accreditation by AAALAC International, a globally recognized organization dedicated to promoting excellence in laboratory... ► Artikel lesen | |
| 04.06. | BIOCYTOGEN-B (02315): FORM OF PROXY FOR THE USE AT THE 2026 SECOND EXTRAORDINARY GENERAL MEETING HELD ON THURSDAY, JUNE 25, 2026 | - | HKEx | ||
| 04.06. | BIOCYTOGEN-B (02315): NOTICE OF THE 2026 SECOND EXTRAORDINARY GENERAL MEETING | 1 | HKEx | ||
| 04.06. | BIOCYTOGEN-B (02315): CIRCULAR FOR THE 2026 SECOND EXTRAORDINARY GENERAL MEETING | 1 | HKEx | ||
| 27.05. | Biocytogen lanciert KI-gestützte RenSuper-Plattform und branchenweit erste voll automatisierte Infrastruktur für die Antikörperentdeckung | 213 | Business Wire | Biocytogen gab heute den Start seiner RenSuper Workstation bekannt, einer KI-gestützten Plattform für die Antikörperentdeckung der nächsten Generation, die sofortigen Zugriff auf eine umfangreiche... ► Artikel lesen | |
| 21.05. | BIOCYTOGEN-B (02315): ARTICLES OF ASSOCIATION | - | HKEx | ||
| 21.05. | BIOCYTOGEN-B (02315): POLL RESULTS OF THE 2025 ANNUAL GENERAL MEETING HELD ON MAY 21, 2026 | - | HKEx | ||
| 07.05. | BIOCYTOGEN-B (02315): CLARIFICATION ANNOUNCEMENT | - | HKEx | ||
| 27.04. | BIOCYTOGEN-B (02315): FIRST QUARTERLY REPORT FOR THE THREE MONTHS ENDED MARCH 31, 2026 | 3 | HKEx | ||
| 23.04. | BIOCYTOGEN-B (02315): FORM OF PROXY OF H SHAREHOLDERS FOR THE USE AT THE 2025 ANNUAL GENERAL MEETING HELD ON THURSDAY, MAY 21, 2026 | - | HKEx | ||
| 23.04. | BIOCYTOGEN-B (02315): NOTICE OF THE 2025 ANNUAL GENERAL MEETING | - | HKEx | ||
| 23.04. | BIOCYTOGEN-B (02315): CIRCULAR FOR THE 2025 ANNUAL GENERAL MEETING | 1 | HKEx | ||
| 21.04. | BIOCYTOGEN-B (02315): 2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE (ESG) REPORT | 1 | HKEx | ||
| 21.04. | BIOCYTOGEN-B (02315): 2025 ANNUAL REPORT | 1 | HKEx | ||
| 15.04. | BIOCYTOGEN-B (02315): DATE OF BOARD MEETING | 1 | HKEx |
1 2 3 Weiter >>
57 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 0,012 | -32,22 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 30.06.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 30.06.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.06.2026ISIN NameBE0003593044 COFINIMMOCA8765111064 TASEKO... ► Artikel lesen | |
| BIOFRONTERA | 2,430 | +4,29 % | PTA-News: Biofrontera AG: Biofrontera berichtet über die Ergebnisse des ersten Quartals 2026 | DJ PTA-News: Biofrontera AG: BIOFRONTERA BERICHTET ÜBER DIE ERGEBNISSE DES ERSTEN QUARTALS 2026
Unternehmensmitteilung für den Kapitalmarkt
Biofrontera AG: BIOFRONTERA BERICHTET ÜBER... ► Artikel lesen | |
| CLINUVEL | 6,368 | +1,34 % | CLINUVEL PHARMACEUTICALS LIMITED: CLINUVEL confirms terms of CEO's Employment Agreement | ||
| EDITAS MEDICINE | 3,120 | -1,89 % | Editas Medicine, Inc.: Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical... ► Artikel lesen | |
| ASEP MEDICAL | 0,100 | 0,00 % | CSE Bulletin: Suspensions - VSBLTY Groupe Technologies Corp., NuRAN Wireless Inc., GOAT Industries Ltd., BYT Holdings Ltd., ASEP Medical Holdings Inc., BioVaxys Technology Corp. | Le 6 mai/May 2026
Effective immediately, the following companies are suspended pursuant to CSE Policy 3. The suspensions are considered Regulatory Halts as defined in National Instrument 23-101 Trading... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 2,790 | -0,71 % | Cellectar Biosciences, Inc.: Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting | Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy Plans to Initiate Phase... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,094 | -1,62 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update | Completed successful End-of-Phase 2 meeting with the FDA and selected onvansertib dose and chemotherapy regimen for planned Phase 3 trial Company to provide detailed data update from Phase 2 CRDF-004... ► Artikel lesen | |
| CLEAN HARBORS | 253,00 | -0,63 % | Öl-Altlasten als Milliardenmarkt: Regulierungsdruck für Chevron und Clean Harbors - Zefiro Methane als Chance | Die Methanemissionen aus stillgelegten und verwaisten Öl- und Gasbohrlöchern in Nordamerika wurden jahrzehntelang drastisch unterschätzt. Wissenschaftliche Untersuchungen der McGill University belegen... ► Artikel lesen | |
| MESOBLAST | 1,357 | +3,00 % | Big Pharma kauft weiter Zukunftstechnologien - Warum Milliarden in Zelltherapien fließen und manche Unternehmen vor einem neuen Marktumfeld stehen | ||
| SPERO THERAPEUTICS | 1,877 | -2,39 % | Spero Therapeutics, Inc.: Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs) | First and only oral carbapenem antibiotic approved in the USApproval based on PIVOT-PO trial demonstrating non-inferiority compared to intravenous treatmentiMore than 3 million cases of cUTIs are... ► Artikel lesen | |
| LIR LIFE SCIENCES | 0,236 | -9,92 % | Lir Life Sciences Corp.: LIR Life Sciences Completes Comparative Animal Study Showing Successful Protamine-Enhanced Permeation Transport of Both Semaglutide and Tirzepatide | VANCOUVER, BC / ACCESS Newswire / June 17, 2026 / LIR Life Sciences Corp. (CSE:SKNY)(OTCPK:BBCMF)(Frankfurt:N790, WKN: A41QA9) ("LIR" or the "Company")is pleased to announce the successful final completion... ► Artikel lesen | |
| PROTALIX BIOTHERAPEUTICS | 1,988 | -0,60 % | Protalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results | Company to host conference call and webcast today at 8:00 a.m. EDT
Elfabrio commercial execution continues following European Commission approval of the 2 mg/kg... ► Artikel lesen | |
| CSTONE PHARMACEUTICALS | 0,600 | +5,78 % | EQS Newswire: CStone Pharmaceuticals: CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) ASCO 2026 Key Highlights | EQS Newswire / 12/06/2026 / 15:02 UTC+8
Shanghai - 12 Jun 2026 - The clinical datasets presented at ASCO 2026 further validate the trispecific synergistic mechanism of CS2009 and support its potential... ► Artikel lesen | |
| PALVELLA THERAPEUTICS | 129,00 | 0,00 % | Palvella Therapeutics Inc.: Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors | Brings more than 25 years of experience advancing and commercializing high-impact therapies for serious diseases, including those with limited or no approved treatment options Extensive public company... ► Artikel lesen | |
| PURPLE BIOTECH | 1,680 | -1,18 % | Purple Biotech Ltd.: Purple Biotech Announces CEO Transition | Gil Efron to Step Down as CEO in August 2026 for Health Considerations; Will Continue to Lead Corporate Development REHOVOT, Israel, March 13, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (NASDAQ/TASE:... ► Artikel lesen |
Das Unternehmen BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 5,000 Euro und damit -2,91 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD finden Sie auf Wallstreet Online.